[somewhat OT] Finished 'The Antidote,' and found it a disappointment. Would recommend anyone taking up the book to skip to the last third and begin with the Incivek launch, and continuing with that of Kalydeco, as what precedes mostly a record of corporate comings and goings without much insight, drama or analysis. The writing is not up to the standard of his earlier book, 'The Billion $ Molecule,' about Vertex's early years. Very little of the founding excitement and perspective recorded in the latter book survives into the former.
Takeaways:
* Dumb title, as it's never clear which of Vertex's two drugs is being referred to, nor can either one, strictly speaking be called an antidote: one kills viruses; the other administers therapy for a genetic flaw.
* The small (relative to the billions of $ poured into Vertex) contributions of money and enthusiasm made by the Cystic Fibrosis Foundation beginning in the 1990s paid handsome dividends both for its disease sufferers and Vertex's stockholders.
Market Data 
Markets 
AI
